Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".
The authors of the manuscript "Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population" respond to a letter to the editor.